622 related articles for article (PubMed ID: 28031235)
21. Histone deacetylase inhibitors repress chondrosarcoma cell proliferation.
Zhu J; Gu J; Ma J; Xu Z; Tao H
J BUON; 2015; 20(1):269-74. PubMed ID: 25778327
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
23. Trichostatin A induces a unique set of microRNAs including miR-129-5p that blocks cyclin-dependent kinase 6 expression and proliferation in H9c2 cardiac myocytes.
Majumdar G; Raghow R
Mol Cell Biochem; 2016 Apr; 415(1-2):39-49. PubMed ID: 26946427
[TBL] [Abstract][Full Text] [Related]
24. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S
Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284
[TBL] [Abstract][Full Text] [Related]
25. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
[TBL] [Abstract][Full Text] [Related]
26. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Chen CQ; Chen CS; Chen JJ; Zhou LP; Xu HL; Jin WW; Wu JB; Gao SM
Mol Cell Biochem; 2013 Nov; 383(1-2):137-48. PubMed ID: 23867991
[TBL] [Abstract][Full Text] [Related]
29. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Davies GF; Ross AR; Arnason TG; Juurlink BH; Harkness TA
Cancer Lett; 2010 Feb; 288(2):236-50. PubMed ID: 19699029
[TBL] [Abstract][Full Text] [Related]
30. Effects of histone deacetylase inhibitors on regenerative cell responses in human dental pulp cells.
Luo Z; Wang Z; He X; Liu N; Liu B; Sun L; Wang J; Ma F; Duncan H; He W; Cooper P
Int Endod J; 2018 Jul; 51(7):767-778. PubMed ID: 28375564
[TBL] [Abstract][Full Text] [Related]
31. High dose of histone deacetylase inhibitors affects insulin secretory mechanism of pancreatic beta cell line.
Yamato E
Endocr Regul; 2018 Jan; 52(1):21-26. PubMed ID: 29453918
[TBL] [Abstract][Full Text] [Related]
32. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Munshi A; Kurland JF; Nishikawa T; Tanaka T; Hobbs ML; Tucker SL; Ismail S; Stevens C; Meyn RE
Clin Cancer Res; 2005 Jul; 11(13):4912-22. PubMed ID: 16000590
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome screening and verification of genes related to metabolism affected by histone deacetylase inhibitors.
Cao JH; Liao WT; Wo C; Xu GR; Xu HX; Li P; Tao Y; Wang P; Lin JR; Deng LR
Yi Chuan; 2015 Sep; 37(9):918-25. PubMed ID: 26399531
[TBL] [Abstract][Full Text] [Related]
36. Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression, Cell Growth Inhibition and Apoptosis Induction in Colon Cancer LS 174T Cell Line.
Sanaei M; Kavoosi F
Asian Pac J Cancer Prev; 2020 Jul; 21(7):2131-2139. PubMed ID: 32711442
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
[TBL] [Abstract][Full Text] [Related]
38. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells.
Brest P; Lassalle S; Hofman V; Bordone O; Gavric Tanga V; Bonnetaud C; Moreilhon C; Rios G; Santini J; Barbry P; Svanborg C; Mograbi B; Mari B; Hofman P
Endocr Relat Cancer; 2011 Dec; 18(6):711-9. PubMed ID: 21946411
[TBL] [Abstract][Full Text] [Related]
39. Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells.
Han RF; Li K; Yang ZS; Chen ZG; Yang WC
Mol Med Rep; 2014 Dec; 10(6):3211-6. PubMed ID: 25269990
[TBL] [Abstract][Full Text] [Related]
40. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
